IDEAYA Biosciences (IDYA) Retained Earnings (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Retained Earnings of -$835.1 million for Q1 2026, down 13.38% sequentially from -$736.5 million in Q4 2025, and down 52787.7% YoY from N/an in Q1 2025.
IDEAYA Biosciences (IDYA) Retained Earnings (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Retained Earnings for 9 years, with the latest figure at -$835.1 million in Q1 2026.
- Quarterly Retained Earnings fell 52787.7% year-over-year to -$835.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$835.1 million (down 52787.7% YoY) and the FY2025 annual result came in at -$736.5 million, down 18.25% from the prior year.
- Retained Earnings retreated to -$835.1 million in Q1 2026 per IDYA's latest filing, from -$736.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at $1.6 million in Q1 2025 and troughed at -$835.1 million in Q1 2026.
- A 5-year average of -$283.7 million and a median of -$259.0 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings sank 65570.53% in 2024, then jumped 207.42% in 2025.
- Over 5 years, Retained Earnings stood at -$2.9 million in 2022, then plunged by 12033.89% to -$348.4 million in 2023, then tumbled by 78.79% to -$622.8 million in 2024, then declined by 18.25% to -$736.5 million in 2025, then dropped by 13.38% to -$835.1 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$835.1 million, -$736.5 million, and -$653.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | -947.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -947.53 Mn |
| Mar 31, 2026 | -835.10 Mn |
| Dec 31, 2025 | -736.54 Mn |
| Sep 30, 2025 | -653.30 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | -622.84 Mn |
| Sep 30, 2024 | -492.53 Mn |
| Jun 30, 2024 | -1.42 Mn |
| Mar 31, 2024 | -387.94 Mn |
| Dec 31, 2023 | -348.36 Mn |
| Sep 30, 2023 | -750,000.00 |
| Jun 30, 2023 | -286.97 Mn |
| Mar 31, 2023 | -259.04 Mn |
| Dec 31, 2022 | -2.87 Mn |
| Sep 30, 2022 | -4.00 Mn |
| Jun 30, 2022 | -3.63 Mn |
| Mar 31, 2022 | -190.76 Mn |
| Dec 31, 2021 | -712,000.00 |
| Sep 30, 2021 | -158.50 Mn |